Wednesday, 30 Jul 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
    Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
    29/07/2025
    Natural Diamond Council Delivers Facts on the Diamond Market’s Trending Topic
    Natural Diamond Council Delivers Facts on the Diamond Market’s Trending Topic
    29/07/2025
    NYSE Content Advisory: Pre-market update + U.S. & EU reach trade deal
    28/07/2025
    Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)
    Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)
    28/07/2025
    Amity Innovation Incubator’s Investor Pitch Day Showcases India’s Next Generation of Disruptive Startups
    Amity Innovation Incubator’s Investor Pitch Day Showcases India’s Next Generation of Disruptive Startups
    28/07/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • july
  • global
  • Business
  • today
  • announced
  • Tech
  • company
  • will
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

PRNW Agency
Last updated: 30/07/2025 12:19 AM
PRNW Agency
Share
4 Min Read
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
SHARE
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples

- Advertisement -

FREMONT, Calif., July 29, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE) to deploy its ultra-sensitive NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 in the Rhineland Study—one of the world’s most comprehensive and innovative longitudinal aging cohorts, as well as in some of the DZNE’s clinical disease specific cohorts. This initiative will profile 23,000 plasma samples to accelerate biomarker discovery and advance understanding of healthy aging and neurodegeneration.

- Advertisement -

“Understanding aging and dementia requires both advanced technology and deeply characterized cohorts,” said Prof. Monique Breteler, Director of Population Health Sciences at DZNE and Principal Investigator of the Rhineland Study. “Integrating Alamar’s multiplex panels into our research opens new opportunities to decode the molecular signatures of brain aging.”

The DZNE Rhineland Study is an ongoing, large-scale population-based cohort designed to investigate determinants of healthy aging and the development of neurodegenerative diseases across the lifespan. By utilizing Alamar’s NULISAseq CNS Disease Panel 120, researchers will be able to measure hundreds of brain-related proteins from minimal blood volumes, with exceptional sensitivity and specificity. Notably, the CNS panel’s ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in plasma represents a transformative advance for early detection and risk stratification of neurodegenerative conditions such as Alzheimer’s disease. In addition, the NULISAseq Inflammation Panel 250 provides the most comprehensive and sensitive profiling of immune-related proteins implicated in aging and neuroinflammation associated with neurodegenerative diseases.

- Advertisement -

The resulting proteomic data will be combined with the study’s extensive clinical, demographic, and imaging datasets, enabling researchers to track protein changes over time, identify early biomarkers, and support the development of precision diagnostics and targeted therapies.

- Advertisement -

“This partnership marks a major step forward in aging and dementia research,” said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. “With NULISA’s unmatched sensitivity and the depth of the DZNE Rhineland Study, we can uncover novel protein biomarkers that reveal the trajectories of cognitive health and disease progression in aging populations.”

This collaboration reflects a shared commitment to scientific rigor, inclusivity, and innovation in neurodegenerative disease research. By capturing diverse aging trajectories in a deeply characterized population, Alamar and DZNE aim to drive earlier diagnosis, improved prognosis, and new therapeutic pathways for age-related brain disorders.

- Advertisement -

About the DZNE Rhineland Study

- Advertisement -

The DZNE (German Center for Neurodegenerative Diseases) Rhineland Study is an ambitious, population-based cohort following thousands of individuals across decades to uncover determinants of healthy aging and neurodegeneration. Detailed clinical, imaging, genetic, and lifestyle data are collected and harmonized to enable deep insights into the aging brain. Learn more about the DZNE at www.dzne.de/en/, and about the DZNE Rhineland Study at www.rheinland-studie.de/en/ 

About Alamar Biosciences, Inc.

- Advertisement -

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com

- Advertisement -

Photo – https://mma.prnewswire.com/media/2739794/German_Center_for_Neurogenerative_Diseases.jpg
Logo – https://mma.prnewswire.com/media/1810182/Alamar_Logo_WhiteOutline_RGB_4x1_Logo_V1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/alamar-biosciences-and-the-german-center-for-neurodegenerative-diseases-dzne-partner-for-landmark-proteomic-profiling-study-in-the-rhineland-study-cohort-302515637.html

- Advertisement -
IPO Bound Pace Digitek Limited Inaugurates BESS Manufacturing Facility in Bidadi, Karnataka
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
4SidesPlay Debuts as South India’s First Language-Driven OTT Platform
Young Welsh Athlete Secures Funding to Revolutionise Wheelchair Rugby League
MSP Recovery Law Firm Secures Major Legal Win for MSP Recovery as Maryland Supreme Court Upholds Validity of Medicare Recovery Assignments for MSP Recovery and Its Healthcare Clients, Paving the Way for Medicare Recovery Rights Being Pursued Against GEICO
TAGGED: and for the(dzne)alamarbiosciencescentercohortdiseasesgermanlandmarkneurodegenerativenewspartnerprofilingproteomicrhinelandstudy
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

AM Best Assigns Credit Ratings to DavidShield Insurance Company
Business

AM Best Assigns Credit Ratings to DavidShield Insurance Company

22/07/2025
Moore Global Named Network of the Year in Unanimous Decision
Health

Moore Global Named Network of the Year in Unanimous Decision

10/07/2025
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
Health

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

20/06/2025
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
Health

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

21/07/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?